Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference CallGlobeNewsWire • 04/21/26
Optum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse PractitionersGlobeNewsWire • 04/13/26
Largest Independent Shareholder of Neuronetics, Inc., Jorey Chernett, Calls for Immediate and Comprehensive Review of Strategic Alternatives, Including Sale of TMS BusinessPRNewsWire • 04/06/26
Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating ResultsGlobeNewsWire • 03/17/26
Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewsWire • 02/10/26
Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewsWire • 11/20/25
TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with DepressionGlobeNewsWire • 11/12/25
Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition PlanGlobeNewsWire • 11/04/25
Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational ExcellenceGlobeNewsWire • 10/30/25
Neuronetics to Report Third Quarter 2025 Financial and Operating Results and Host Conference CallGlobeNewsWire • 10/21/25
New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)GlobeNewsWire • 09/17/25
Neuronetics to Present at the Canaccord Genuity 45th Annual Growth ConferenceGlobeNewsWire • 08/04/25
NeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed AdolescentsGlobeNewsWire • 07/30/25
Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook's Personalized Care Trial ProgramGlobeNewsWire • 06/10/25